Intervacc is trading 18.19% down at €0.07, with no clear company-specific catalyst identified for August 20, 2026.
- Intervacc’s Q2 2026 earnings release is expected on August 20, with consensus revenue of 4.8 million and anticipated earnings of -0.05 per share.
- The broader biotech sector was rising and market conditions were mixed, so broader sentiment does not clearly explain the decline.
- The move remains unexplained pending potential earnings-related disclosure.